U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16ClNO3
Molecular Weight 257.713
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MECLOFENOXATE

SMILES

CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1

InChI

InChIKey=XZTYGFHCIAKPGJ-UHFFFAOYSA-N
InChI=1S/C12H16ClNO3/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11/h3-6H,7-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C12H16ClNO3
Molecular Weight 257.713
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://toppharma.co.uk/top-pharma-product/powder-for-injection/meclofenoxate/

Meclofenoxate (INN, BAN) (brand name Lucidril), also known as centrophenoxine, is a cholinergic nootropic used as a dietary supplement and drug in the treatment of symptoms of senile dementia and Alzheimer's disease. Meclofenoxate has been shown in studies to be effective in enhancing the memory and in improving the cognitive functions of the elderly. Some studies even suggest that Meclofenoxate has the ability to reverse the signs of brain aging. While claims about its ability as a nootropic agent have not been fully established in clinical trials, some studies do strongly suggest that it is indeed very effective in improving memory retention and recall. Meclofenoxate HCL Powder for Injection is also indicated for the following conditions: comma; skull and brain trauma; following a stroke; encephalopathy; mental disorders (in combination with psychotropic agents); mental and psychomotor retardation in children; brain intoxication; alcohol psychoses; neuritis and polyneuritis. The main mechanism of action of Meclofenoxate is generally believed to be cholinergic in nature. As an efficient transporter of DMAE, Meclofenoxate encourages the production of choline in the brain, which is then synthesized into acetylcholine. The more acetylcholine neurotransmitters in the brain, the better and more efficient the cognitive functions will be. Meclofenoxate also increases cellular membrane phospholipids

CNS Activity

Curator's Comment: Meclofenoxate increases the dimethylethanolamine or DMAE levels in the brain. DMAE is a precursor of acetylcholine, an important neurotransmitter in the brain believed to be responsible for most of the cognitive processes within it.

Approval Year

Conditions

Conditions

PubMed

PubMed

TitleDatePubMed
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?
2001 Feb
Cholinergic medication for neuroleptic-induced tardive dyskinesia.
2002
Effect of centrophenoxine on water-immersion restraint stress- and chemically-induced gastric ulcers in rats.
2003
Brain cholinesterases: III. Future perspectives of AD research and clinical practice.
2004
Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats.
2004 Dec
Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.
2004 Nov
Therapy of hearing disorders - conservative procedures.
2005
Reversal of an aluminium induced alteration in redox status in different regions of rat brain by administration of centrophenoxine.
2006 Oct
Further evidence of centrophenoxine mediated protection in aluminium exposed rats by biochemical and light microscopy analysis.
2007 Dec
Stability-indicating electrochemical methods for the determination of meclophenoxate hydrochloride and pyritinol dihydrochloride using ion-selective membrane electrodes.
2007 Jan
Kinetic study on the degradation of meclophenoxate hydrochloride in alkaline aqueous solutions by high performance liquid chromatography.
2007 Jan
Treatment of urinary incontinence after stroke in adults.
2008 Jan 23
[Effects of piracetam and meclofenoxate on the brain NMDA and nicotinic receptors in mice with different exploratory efficacy in the cross maze test].
2008 Jan-Feb
Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
2008 Mar 27
[Effects of nicotinic cholinoreceptor ligands and nootropic drugs on the spontaneous exploratory activity in a labyrinth in mice].
2008 May-Jun
Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study.
2008 Sep
Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
2009 Nov
[Transcutaneous electrical acupoint stimulation combined with auricular acupoint sticking for treatment of primary nocturnal enuresis].
2010 May
A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma.
2010 May-Jun
Patents

Patents

Sample Use Guides

Elderly people with significant intellectual decline may chose 3 to 6 Centrophenoxine tablets (250 mg) per day taken preferably with breakfast and lunch, in order to avoid insomnia. For the non-elderly wishing to utilize the brain boosting benefits of Centrophenoxine, perhaps only 1 or 2 Centrophenoxine tablets (250 mg each) daily with breakfast or lunch.
Route of Administration: Oral
In Vitro Use Guide
The superoxide radical scavenging ability of centrophenoxine (CPH/MECLOFENOXATE) was studied in vitro using the method of pyrogallol autoxidation, cytochrome c reduction and photoxidation of o-dianisidine in salt-free assay media and in the presence of increasing NaCl or KCl concentrations. The CPH proved to be a superoxide radical scavenger in all three systems used, however, the rate constant for this reaction was rather low (1.7 X 10(2) M-1 s-1).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:09 GMT 2023
Edited
by admin
on Fri Dec 15 15:12:09 GMT 2023
Record UNII
C76QQ2I0RG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MECLOFENOXATE
INN   MI   WHO-DD  
INN  
Official Name English
ANALUX
Brand Name English
DIMETHYLAMINOETHYL P-CHLOROPHENOXYACETATE
Common Name English
CENTROPHENOXINE
Common Name English
Meclofenoxate [WHO-DD]
Common Name English
ANP-235
Code English
MECLOFENOXANE
Common Name English
CETREXIN
Brand Name English
NSC-169411
Code English
meclofenoxate [INN]
Common Name English
(4-CHLOROPHENOXY)ACETIC ACID 2-(DIMETHYLAMINO)ETHYL ESTER
Systematic Name English
MECLOFENOXATE [MI]
Common Name English
2-(DIMETHYLAMINO)ETHYL(P-CHLORPHENOXY)ACETATE
Common Name English
PROSERYL
Brand Name English
Classification Tree Code System Code
WHO-VATC QN06BX01
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
WHO-ATC N06BX01
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
DSLD 1889 (Number of products:4)
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
Code System Code Type Description
MESH
D002504
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
WIKIPEDIA
MECLOFENOXATE
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID9046940
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-116-3
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
NSC
169411
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
DRUG BANK
DB13758
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
PUBCHEM
4039
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
NCI_THESAURUS
C174654
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
EVMPD
SUB08679MIG
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
CAS
51-68-3
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
DRUG CENTRAL
1651
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
INN
1083
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
SMS_ID
100000081777
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
MERCK INDEX
m7121
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY Merck Index
FDA UNII
C76QQ2I0RG
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL64545
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY
RXCUI
2228
Created by admin on Fri Dec 15 15:12:09 GMT 2023 , Edited by admin on Fri Dec 15 15:12:09 GMT 2023
PRIMARY RxNorm
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY